Hydrosome Labs, a US biotechnology company focused on ultrafine bubble (UFB) technology, on Tuesday reported new findings from a study with Biocell Energetics, a venture from the University of Birmingham in the UK.
According to Hydrosome, the research demonstrated that winemaking/brewing yeast (Saccharomyces bayanus) grown in media infused with UFB water exhibited faster glucose metabolism and as much as a 31% increase in oxygen uptake rates compared to conventional fermentation using deionised water. These results suggest that Hydrosome Technology can significantly increase production output without requiring costly infrastructure changes.
The study involved real-time oxygen consumption monitoring and glucose utilisation tracking of UFBs on yeast respiration and metabolic performance. Findings include: a 31% increase in peak oxygen uptake at high UFB concentrations and 22% at medium levels versus a control without UFBs; up to 6X faster initial glucose consumption compared to the control; and a clear dose-response effect between UFB concentration and respiratory performance.
These results build on a 400-litre pilot study by Hydrosome Labs and the University of Illinois on E. coli fermentation, in which continuous UFB infusion doubled cell output, accelerated doubling time, and improved glucose utilisation by nearly threefold. That study also recorded a 14% increase in oxygen uptake, further validating UFBs as a tool for improving fermentation efficiency.
Hydrosome Labs says that it is partnering with companies across industries, including precision fermentation, functional beverages, and personal care, to scale these benefits through clean-label, chemical-free delivery systems.
Airiver medical receives FDA approval for central airway stenosis trial
INOVIO to begin rolling submission of BLA for INO-3107
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
LivaNova announces commercial launch of Essenz Perfusion System in China
Precigen's PAPZIMEOS granted US FDA approval to treat with recurrent respiratory papillomatosis
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis